The safety, efficacy and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation

Clinical Infectious Diseases

Volumn 44, Issue 11, 2007, Pages 1475-1483

  Winston, Alan ^a,b,d   Mallon, Patriclc W G ^a,b   Satchell, Claudette ^a   MacRae, Karen ^b   Williams, Kenneth M ^b   Schutz, Malte ^c   Law, Matthew ^c   Cooper, David A ^a,b   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c HOFFMANN LA ROCHE INC   (United States)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; JAUNDICE; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SAQUINAVIR; TREATMENT OUTCOME;

EID: 34249027965     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/517507     Document Type: Article

References (26)

1. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-6.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-4.
3. d'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12:1631-7.
4. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
5. Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001; 2:166-73.
6. Miro O, Lopez S, Cardellach F, Casademont J. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther 2005; 10(Suppl 2):M73-81.
7. Seminari E, Guffanti M, Villani P, et al. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol 2005; 61:545-9.
8. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18:1291-7.
9. Bittner B, Riek M, Holmes B, Grange S. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther 2005; 10:803-10.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2005. Top HIV Med 2005; 13:125-31.
11. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-66.
12. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-91.
13. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-94.
14. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: a randomized, controlled, open label, pilot, clinical trial (OK Study) - 48 weeks analysis [abstract WePe12.3C05]. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Stockholm: International AIDS Society, 2005.
15. Kahlert C, Hupfer M, Wagels T, et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-7.
16. Vernazza P, Daneel S, Schiffer V, et al. Viral suppression in CSF and genital tract on ATV/r-only maintenance (ATARITMO-Study). In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Stockholm: International AIDS Society, 2005.
17. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-14.
18. Cameron W, da Silva B, Arribas J, et al. A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (study M03-613) [abstract THLB0201]. In: Program and abstracts of the 16th International AIDS Conference (Toronto). Stockholm: International AIDS Society, 2006.
19. Delfraissy JF, Flandre P, Delaugerre C, et al. MONARK Trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/lamivudine (AZT/3TC) in antiretroviral-naive patients [abstract THLB0202]. In: Program and abstracts of the 16th International AIDS Conference (Toronto). Stockholm: International AIDS Society, 2006.
20. Arribas J, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: forty-eight week results of a randomized, controlled, open-label, clinical trial (OK04 Study) [abstract THLB0203]. In: Program and abstracts of the 16th International AIDS Conference (Toronto). Stockholm: International AIDS Society, 2006.
21. O'Mara E, Mummaneni V, Bifano M, et al. Pilot study of the interaction between BMS-232632 and ritonavir [poster 740]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
22. trough is associated with efficacy and safety: definition of therapeutic range [abstract 645]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
23. Phillips AN, Youle M, Lampe F, et al. CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. AIDS 2002; 16:1073-5.
24. + T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-13.
25. Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 57:806-9.
26. Vernazza P, Daneel S, Schiffer V, et al. Risk of CNS-compartment failure on PI monotherapy (ATARITMO-study) [abstract WEPE0073]. In: Programs and abstracts of the 16th International AIDS Conference (Toronto). Stockholm: International AIDS Society, 2006.